
ALT Cumulative-incidence plots are shown for the primary composite end point (Panel A) and for its components — death from any cause (Panel B); appropriate implantable cardioverter–defibrillator (ICD) therapy or ventricular tachycardia with a rate of more than 125 beats per minute lasting more than 30 seconds, documented by electrocardiography (ECG) or the ICD cardiac electrogram (Panel C); hospitalization for cardiac arrhythmia (Panel D); and hospitalization for heart failure (Panel E).

ALT Kaplan–Meier curves shown for a composite of cardiovascular death, myocardial infarction (MI), stroke, systemic embolism, coronary revascularization, or acute limb ischemia (the primary efficacy outcome) (Panel A), major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria (the key secondary safety outcome) (Panel B), and death from any cause (a secondary efficacy outcome) (Panel C).
![Panel A: A figure showing the incidence of net adverse clinical and cerebrovascular events, defined as a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or major bleeding (defined by the Bleeding Academic Research Consortium [BARC] as a bleeding event of type 3 or 5) (the primary outcome). Panel B: A figure showing the incidence of BARC type 2, 3, or 5 bleeding (clinically relevant bleeding) (the main secondary outcome).](https://pbs.twimg.com/media/GzxPgM9bIAAFMmb.png?name=small&format=webp)
ALT Panel A: A figure showing the incidence of net adverse clinical and cerebrovascular events, defined as a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or major bleeding (defined by the Bleeding Academic Research Consortium [BARC] as a bleeding event of type 3 or 5) (the primary outcome). Panel B: A figure showing the incidence of BARC type 2, 3, or 5 bleeding (clinically relevant bleeding) (the main secondary outcome).

























